Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Addressing the critical challenge of cancer overdiagnosis

Proscia
By Author Proscia | November 17, 2020

Proscia has announced that NASA’s Jet Propulsion Laboratory (JPL) and the National Cancer Institute Consortium for Molecular Characterization of Screen-Detected Lesions (MCL) have deployed its Concentriq platform to advance biomedical research. Through this collaborative programme, coordinated by Baylor College of Medicine, JPL is digitising a repository of valuable pathology data to make it readily accessible to researchers from across the seven sites of the MCL. Researchers will use the data to unlock new insights that combat the growing challenge of overdiagnosis, which results in unnecessary treatment of cancers that would have never caused medical problems for the patient.

Our website uses cookies. By using this site, you agree to its use of cookies.